View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Simon Brun
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Simon Brun
ABGSC Shipping & Transport Research ... (+3)
  • ABGSC Shipping & Transport Research
  • Henrik Bartnes
  • Petter Nystrøm
ABGSC Shipping & Transport Research ... (+3)
  • ABGSC Shipping & Transport Research
  • Henrik Bartnes
  • Petter Nystrøm

Sep figures; Neutral

Group sales NOK 3.5bn, +1% vs. cons. Limited outlook comments, but do state "encouraging" momentum

ABGSC Financials Research ... (+4)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Patrik Brattelius
  • Simon Brun
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Simon Brun
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Philip Ekengren
ABGSC Shipping & Transport Research ... (+3)
  • ABGSC Shipping & Transport Research
  • Henrik Bartnes
  • Petter Nystrøm

Aug sales in-line

Group sales NOK 3.77bn, basically in-line. Limited outlook comments, but do say "solid bookings"

Ambea AB: 1 director

A director at Ambea AB bought 75,000 shares at 126.000SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Oncopeptides AB: 2 directors

A director at Oncopeptides AB bought 56,820 shares at 4.400SEK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Interim Report Q2 2025: Commercial and operational agility drove marke...

Interim Report Q2 2025: Commercial and operational agility drove market share gains and 46% EBITA growth Highlights The Hearing division delivered 8% organic revenue growth driven by broad-based market share gains of ReSound Vivia across global markets growing below structural trends. The strong growth led to 12% growth in divisional profit, equaling a divisional profit margin of 36% driven by operating leverageThe Enterprise division was – as expected – challenged by market uncertainty due to the global trade environment. The organic revenue growth was -7% due to the market uncertainty an...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Financials Research ... (+4)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
  • Simon Brun
 PRESS RELEASE

GN introduces ReSound Enzo IA: Exceptional speech understanding and al...

GN introduces ReSound Enzo IA: Exceptional speech understanding and all-day battery life – in the world’s smallest rechargeable Super Power hearing aid BALLERUP, Denmark, Aug. 12, 2025 (GLOBE NEWSWIRE) -- GN, a global leader in hearing technology, announced today the launch of ReSound Enzo™ IA, the world's smallest rechargeable Super Power hearing aid,1 representing a huge leap forward in sound quality for people with severe to profound hearing loss. Understanding speech, especially in noisy environments, is the biggest challenge for Super Power users. ReSound Enzo IA, benefitting from G...

ABGSC Shipping & Transport Research ... (+3)
  • ABGSC Shipping & Transport Research
  • Henrik Bartnes
  • Petter Nystrøm

Sales 1% below on lower load

Group sales NOK 4.76bn, 1% below us. We reiterate that Q3 EBIT est looks +10% too high

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch